Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06975644 | Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) | not yet recruiting | N/A | 55 | Zhejiang Provincial People's HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT05406635 | Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer(HER2BIC) | recruiting | N/A | 220 | Odense University HospitalOTHER | 1 | Apr 8, 2025 |
| clinicaltrials |
| NCT03460067 | Omission of Radiation in Patients With Her-2 Positive Breast Cancer | active not recruiting | N/A | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03715959 | Nipple Aspirate Fluid in Detecting Breast Cancer | completed | N/A | 2 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03881605 | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC(SYMPToM) | active not recruiting | N/A | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782698 | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients(HoPEx-Breast) | active not recruiting | N/A | 50 | Centro Hospitalar Universitário de Santo AntónioOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06718335 | Pyrotinib in HER2-positive Early Breast Cancer | not yet recruiting | N/A | 156 | Nie JianyunOTHER | 0 | Dec 11, 2024 | clinicaltrials |
| NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | not yet recruiting | N/A | 60 | University Hospital of CologneOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05982626 | Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer | unknown | N/A | 10 | Huashan HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06330012 | The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients. | recruiting | N/A | 50 | Samsung Medical CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06281210 | Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery(BETTY-CRASY) | recruiting | N/A | 77 | European Institute of OncologyOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06259162 | LAG3 Expression in Triple Negative Breast Cancer | recruiting | N/A | 128 | Samsung Medical CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | terminated | N/A | 36 | Centre Jean PerrinOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01712815 | PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer | terminated | N/A | 12 | University of Southern CaliforniaOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05750693 | PIK3CA in HER2+ BC and pCR Trial | unknown | N/A | 58 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03750240 | Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy | terminated | N/A | 2 | NYU Langone HealthOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.(REVER) | terminated | N/A | 4 | Institut Claudius RegaudOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03457779 | Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer | completed | N/A | 16 | Baylor Research InstituteOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT03655353 | A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer(Affibody-3) | unknown | N/A | 160 | Henrik LindmanOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04582955 | Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy | unknown | N/A | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04281641 | Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer(PHC-BC) | recruiting | N/A | 94 | Fudan UniversityOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT04225858 | Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy(ASICS) | not yet recruiting | N/A | 340 | The Netherlands Cancer InstituteOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03609671 | Emotions Immunology and Breast Cancer | completed | N/A | 17 | Luz A. Venta, MDOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03947242 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer. | unknown | N/A | 48 | Henan Cancer HospitalOTHER_GOV | 0 | May 15, 2019 | clinicaltrials |
| NCT03847818 | Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer | unknown | N/A | 268 | Shandong UniversityOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT01936961 | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors(I-CREST) | withdrawn | N/A | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01292083 | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Feb 6, 2014 | clinicaltrials |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 28, 2014 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2025source: clinicaltrials